Sutimlimab's 46% non-response rate remains unaddressed after two rival programs exited cold agglutinin disease.
Sutimlimab (Enjaymo, Recordati Rare Diseases) has been the only FDA-approved therapy for cold agglutinin disease (CAD) since its February 4, 2022 approval, an intravenous anti-C1s classical-complement inhibitor dosed every two weeks for life. Its own pivotal CARDINAL trial found that 54% of patients met the composite hemoglobin-response endpoint, meaning 46% did not; responders gained a mean 2.6 g/dL in hemoglobin and 71% avoided transfusion between weeks 5 and 26 (Röth et al., N Engl J Med, 2021). The trial leaves nearly half of the treated population, and every patient's indefinite dosing burden, unresolved.
CAD affects an estimated 5,000 patients in the US. Sutimlimab's published wholesale acquisition cost implies annual treatment cost of roughly $259,000-$302,000 per patient, and a Yale-led cost-effectiveness analysis put its incremental cost-effectiveness ratio at $2.34 million per QALY against a $150,000 willingness-to-pay threshold, with standard-of-care favored in 100% of 10,000 probabilistic-sensitivity iterations (Ito et al., Am J Hematol, 2024). No formal ICER review of sutimlimab has been published to date. A second entrant should expect payers to demand outcomes-based contracting or a materially lower net price before granting parity access.
Two next-generation complement inhibitors entered cold agglutinin disease after sutimlimab's approval, both discontinued.
| Candidate / Mechanism | Furthest CAD Stage Reached | Current Status |
|---|---|---|
| Sutimlimab (Enjaymo), anti-C1s inhibitor, IV q2w | Phase 3 (CARDINAL, CADENZA) | FDA-approved Feb 4, 2022; only approved CAD therapy |
| Pegcetacoplan (Apellis/Sobi), C3 inhibitor, SC 2x/week | Phase 3 (CASCADE) | Discontinued 2024; sponsor cited reduced medical need and a thin eligible population |
| Iptacopan (Novartis), oral Factor B inhibitor | Phase 2 basket trial | Terminated 2023 |
| Riliprubart / SAR445088 (Sanofi), next-gen anti-C1s | Phase 1b | Positive proof-of-concept; no CAD Phase 3 currently registered |
Sources: Röth A et al., N Engl J Med. 2021;384(14):1323-1334 (CARDINAL); Ito S et al., Cost-effectiveness of sutimlimab in cold agglutinin disease, Am J Hematol. 2024;99:1475-1484; ClinicalTrials.gov NCT05096403 (CASCADE); ClinicalTrials.gov NCT05086744 (Novartis iptacopan basket trial); Röth A et al., Blood. 2024;143(8):713 (riliprubart Phase 1b).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Analysis of the CARDINAL/CADENZA non-responder subgroup and the clinical profile a differentiated agent would need to address
Delivers
- A read on the CASCADE and Novartis basket-trial discontinuations, and the achievable registrational population size for a follow-on program
Delivers
- A payer-posture assessment built from sutimlimab's own $2.34M/QALY ICER precedent and the discipline it sets for the next entrant
Custom brief delivered in 72 hours.
Commission this briefWhat's inside
- Sutimlimab's 46% non-response rate as the unresolved gap
- Pressure-tested against the two discontinued rival programs
- CARDINAL/CADENZA response data
- Dosing burden and durability considerations
- CASCADE trial discontinuation
- Novartis basket-trial termination
- Riliprubart Phase 1b data
- Povetacicept and zanubrutinib basket/investigator trials
- Sutimlimab's $2.34M/QALY ICER finding
- Outcomes-based contracting implications for a new entrant
- Why every pipeline status claim is verified against each candidate's current ClinicalTrials.gov record rather than company pipeline slides
- How the $2.34 million per QALY cost-effectiveness figure and its 100% probabilistic-sensitivity finding trace to a single peer-reviewed analysis
- Whether a new CAD program should target sutimlimab's 46% non-responder population specifically, given why pegcetacoplan and iptacopan exited
- What price and evidence package would let a second CAD therapy clear the payer scrutiny sutimlimab's $2.34M/QALY finding created
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
This assessment draws on the FDA-approved label and pivotal trial data for sutimlimab, direct queries of the ClinicalTrials.gov registry for every CAD-specific interventional trial identified, and the published cost-effectiveness literature. Pipeline status for each named candidate was confirmed against its current ClinicalTrials.gov record rather than company pipeline slides, to distinguish an active program from a discontinued one.
Cost-effectiveness figures, a $2.34 million per QALY ICER and 100% probabilistic-sensitivity preference for standard-of-care, are drawn from Ito S et al., Cost-effectiveness of sutimlimab in cold agglutinin disease, Am J Hematol. 2024;99:1475-1484.
- CARDINAL trial 54%/46% response split verified against Röth A et al., N Engl J Med. 2021;384(14):1323-1334
- All named pipeline candidates verified live against ClinicalTrials.gov records, not company pipeline claims
- Cost-effectiveness figures verified against Ito et al., Am J Hematol. 2024;99:1475-1484; confirmed no formal ICER review of sutimlimab has been conducted
Frequently asked questions
Commission this assessment
AXLRx Cold Agglutinin Disease Launch Readiness is built for commercial and market access teams evaluating entry against sutimlimab's incumbency and the discontinued next-generation pipeline. Custom brief in 72 hours.
Specify indication, geography, and launch timeline.
AXLRx analyst confirms pathway assumptions, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.